Login to Your Account



Up-front Cash/Equity Payment of $60M

Baxter, Cell Therapeutics Sign JAK[ed] Up Myelofibrosis Deal

By Catherine Shaffer
Staff Writer

Friday, November 15, 2013
Fresh from a special protocol assessment agreement with the FDA, Cell Therapeutics Inc. has snagged a lucrative licensing deal with Baxter International Inc. for its Janus kinase (JAK) inhibitor, pacritinib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription